Search Result

Results for "

FASN inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Fatty Acid Synthase (FASN) (29) Antibiotic (2) Apoptosis (9) Bacterial (2) Fungal (1) Isotope-Labeled Compounds (1) SARS-CoV (2)
By Research Areas:	Cancer (24) Infection (4) Inflammation/Immunology (2) Metabolic Disease (9)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Fatty Acid Synthase (FASN)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145809

FASN-IN-5	Fatty Acid Synthase (FASN)	Metabolic Disease Inflammation/Immunology Cancer
FASN-IN-5 (example 11), a *FASN* inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer, immunological disorders, and obesity .

HY-110354

UCM05 G28UCM	Fatty Acid Synthase (FASN) Bacterial Antibiotic	Infection Cancer
UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. UCM05 is a Filamentous temperature-sensitive protein Z (FtsZ) inhibitor and inhibits the growth of the Gram-positive bacterium B. subtilis with MIC values of 100 μM but lack activity on the Gram-negative bacterium E. coli.

HY-12648A

FASN-IN-4 tosylate 3 Publications Verification	Fatty Acid Synthase (FASN) SARS-CoV	Infection Metabolic Disease
FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (FASN) with an IC₅₀ of 10 nM (WO2012064642A1, compound 29) . FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC₅₀ of 18.6 nM .

HY-111777

FASN-IN-1 1 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56 .

HY-U00436

FASN-IN-3	Fatty Acid Synthase (FASN)	Cancer
FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A .

HY-117769

GSK837149A	Fatty Acid Synthase (FASN)	Metabolic Disease
GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on *FASN* and selectivity for type I *FASN* (K_i=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer .

HY-111551

FT113 2 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
FT113 is a potent and orally active fatty acid synthase (FASN) inhibitor, with an IC₅₀ of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC₅₀, 90 nM). FT113 shows anti-proliferative activity, and exhibits anti-cancer activity both in vitro and in vivo .

HY-120394

TVB-3166 5+ Cited Publications	Fatty Acid Synthase (FASN) Apoptosis	Cancer
TVB-3166 is an orally-available, reversible, and selective fatty acid synthase (FASN) inhibitor with IC₅₀s of 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis, respectively. TVB-3166 induces apoptosis, and inhibits in-vivo xenograft tumor growth .

HY-12648

FASN-IN-4	Fatty Acid Synthase (FASN) SARS-CoV	Infection Metabolic Disease
FASN-IN-4 is a potent inhibitor of fatty acid synthase (FASN) with an IC₅₀ of 10 nM (WO2012064642A1, compound 29) . FASN-IN-4 also inhibits SARS-CoV-2 with an EC₅₀ of 18.6 nM .

HY-155282

FASN-IN-6	Fatty Acid Synthase (FASN) Bacterial	Inflammation/Immunology
FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively .

HY-12364A

trans-C75 (±)-C75	Fatty Acid Synthase (FASN)	Cancer
trans-C75 ((±)-C75) is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (FASN) inhibitor.

HY-112522

HS79	Fatty Acid Synthase (FASN)	Cancer
HS-79 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-79 is able to inhibit the incorporation of tritiated acetate into lipids with an IC₅₀ of 1.57 μM.

HY-112522A

HS80	Fatty Acid Synthase (FASN)	Cancer
HS-80 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-80 is able to inhibit the incorporation of tritiated acetate into lipids with an IC₅₀ of 7.13 μM.

HY-12364

C75 Maximum Cited Publications 26 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM . C75 is a potent CPT1A activator .

HY-B0218

Orlistat 10+ Cited Publications Tetrahydrolipstatin; Ro-18-0647	Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease Cancer
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .

HY-158649

Fasnall benzenesulfonate	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Fasnall benzenesulfonate is the benzenesulfonate salt form of Fasnall (HY-121250). Fasnall benzenesulfonate is the inhibitor for fatty acid synthase (FASN) with IC₅₀ of 3.7 μM. Fasnall benzenesulfonate inhibits the proliferation and induces apoptosis in breast cancer cells. Fasnall benzenesulfonate exhibits antitumor efficacy in mice .

HY-121250

Fasnall	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Fasnall is a selective fatty acid synthase (FASN) inhibitor with an IC₅₀ of 3.71 μM. Fasnall induces apoptosis in HER2 ⁺ breast cancer cell lines. Fasnall shows potent anti-tumor activities .

HY-124628

IPI-9119	Fatty Acid Synthase (FASN)	Cancer
IPI-9119 is an orally active, selective and irreversible *FASN* inhibitor with an IC₅₀ of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models .

HY-N2486

Desoxyrhaponticin 1 Publications Verification	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .

HY-112829

Denifanstat 2 Publications Verification TVB-2640; FASN-IN-2; ASC-40	Fatty Acid Synthase (FASN)	Metabolic Disease Cancer
Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC₅₀ of 0.052 μM and an EC₅₀ of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research .

HY-12364B

(−)-C75	Fatty Acid Synthase (FASN)	Cancer
(−)-C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM . C75 is a potent CPT1A activator .

HY-A0210

Cerulenin 5+ Cited Publications	Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic	Infection Metabolic Disease Cancer
Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies .

HY-B0218S

Orlistat-d3 Tetrahydrolipstatin-d₃; Ro-18-0647-d₃	Isotope-Labeled Compounds Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease
Orlistat-d3 is a deuterated labeled Orlistat . Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity .?Anti-atherosclerotic?effect .

HY-B0218R

Orlistat (Standard) 10+ Cited Publications Tetrahydrolipstatin (Standard); Ro-18-0647 (Standard)	Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease Cancer
Orlistat (Standard) is the analytical standard of Orlistat. This product is intended for research and analytical applications. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .

HY-120062

TVB-3664 1 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
TVB-3664 is an orally available, reversible, potent, selective and highly bioavailable fatty acid synthase (FASN) inhibitor, with IC₅₀ values of 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively. TVB-3664 significantly reduces tubulin palmitoylation and mRNA expression .

HY-N2486R

Desoxyrhaponticin (Standard)	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .

HY-12325

GSK2194069 3 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
GSK2194069 is a potent inhibitor of β-ketoyl reductase (KR) of fatty acid synthase (FASN), with an IC₅₀ value of 7.7 nM. GSK2194069 shows specifically inhibitory effect on FAS expressing cancer cells, by acting potent efficacy on acetoacetyl-CoA, NADPH with IC₅₀ or K_i values of 4.8 nM and 5.6 nM, respectively .

HY-149540

CTL-06	Fatty Acid Synthase (FASN)	Cancer
CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC₅₀: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

HY-149541

CTL-12	Fatty Acid Synthase (FASN)	Cancer
CTL-12 is an inhibitor of fatty acid synthase (FASN) (IC₅₀: 2.5 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2486

Desoxyrhaponticin 1 Publications Verification	Structural Classification Monophenols Stilbenes Classification of Application Fields Polygonaceae Source classification Rheum rhabarbarum Linnaeus Phenols Plants Rheum tanguticum Disease Research Fields Cancer	Fatty Acid Synthase (FASN) Apoptosis
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .

HY-A0210

Cerulenin 5+ Cited Publications	Structural Classification Microorganisms Antifungal Classification of Application Fields Antibiotics Source classification Metabolic Disease Mammalian Cell Culture Disease Research Anticancer Disease Research Fields Other Antibiotics	Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic
Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies .

HY-N2486R

Desoxyrhaponticin (Standard)	Structural Classification Monophenols Stilbenes Polygonaceae Source classification Rheum rhabarbarum Linnaeus Phenols Plants Rheum tanguticum	Fatty Acid Synthase (FASN) Apoptosis
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .

Cat. No.	Product Name	Chemical Structure

HY-B0218S

Orlistat-d3
Orlistat-d3 is a deuterated labeled Orlistat . Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity .?Anti-atherosclerotic?effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

FASN inhibitor

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products